SCHEMBL6923142

SCHEMBL6923142

Cc1cc(C(=O)CN2CCCCC2)c(C)n1-c1ccc(N)cc1

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.81
HPGD P15428 3/20 0.81
USP14 P54578 8/20 0.78
RAB9A P51151 6/20 0.78
KDM4E B2RXH2 4/20 0.78
NPC1 O15118 4/20 0.78
USP7 Q93009 3/20 0.78
USP5 P45974 2/20 0.78
POLB P06746 1/20 0.63
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
MAPT P10636 2/20 0.52
ALDH1A1 P00352 2/20 0.48
HTT P42858 2/20 0.47
MITF O75030 1/20 0.46
HKDC1 Q2TB90 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16079020 0.90 SMN1; SMN2 (1.00) SMN1; SMN2HPGDUSP14RAB9AKDM4E
SCHEMBL6923320 0.89 SMN1; SMN2 (0.65) SMN1; SMN2HPGDUSP14RAB9AKDM4E
SCHEMBL23524510 0.89 SMN1; SMN2 (0.83) SMN1; SMN2HPGDUSP14RAB9AKDM4E
SCHEMBL6922583 0.88 SMN1; SMN2 (0.97) SMN1; SMN2HPGDUSP14RAB9AKDM4E
SCHEMBL17949752 0.88 SMN1; SMN2 (0.78) SMN1; SMN2HPGDUSP14RAB9AKDM4E
SCHEMBL6921663 0.88 RAB9A (0.82) SMN1; SMN2HPGDUSP14RAB9AKDM4E
SCHEMBL6922465 0.88 USP14 (1.00) SMN1; SMN2HPGDUSP14RAB9AKDM4E
SCHEMBL17949751 0.88 USP14 (1.00) SMN1; SMN2HPGDUSP14RAB9AKDM4E
SCHEMBL6921406 0.88 SMN1; SMN2 (1.00) SMN1; SMN2HPGDUSP14RAB9AKDM4E
SCHEMBL6922448 0.88 SMN1; SMN2 (0.81) SMN1; SMN2HPGDUSP14RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 US disclosed
EP-2528911-B1 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY HARVARD COLLEGE (US) 2017-10-25 EP disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 US disclosed
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-11-26 US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 US disclosed
WO-2014116228-A1 USP14 INHIBITORS FOR TREATING OR PREVENTING VIRAL INFECTIONS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-07-31 WO disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 US disclosed
WO-2011094545-A2 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections USP14, USP1, USP13 SMN1; SMN2 1593/4885HPGD 2794/4885USP14 1/4885
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSMB11, PSME3 SMN1; SMN2 307/4885HPGD 4149/4885USP14 6/4885
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSME3, PSMB11 SMN1; SMN2 307/4885HPGD 4170/4885USP14 12/4885
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation HSPA2, HSPBP1, HSPH1 SMN1; SMN2 544/4885HPGD 3689/4885USP14 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.